tucatinib,trastuzumab
seagen
john strickler, md, , discusses an analysis of the phase 2 mountaineer trial, in which tucatinib plus trastuzumab demonstrated clinically meaningful antitumor activity in metastatic #colorectalcancer. #wcgic2022 watch the video: 
Oncology Learning Network® is an online resource for the latest news and updates in oncology practice.